Fig. 1: LZ-101 inhibits the viability of human non-small-cell lung cancer cells. | Cell Death & Disease

Fig. 1: LZ-101 inhibits the viability of human non-small-cell lung cancer cells.

From: LZ-101, a novel derivative of danofloxacin, induces mitochondrial apoptosis by stabilizing FOXO3a via blocking autophagy flux in NSCLC cells

Fig. 1

a LZ-101 molecular structure (C26H23FN6O, Molecular Weight: 454.19). Effect of LZ-101 on the viability of human non-small cell lung cancer cells. MTT assay was used to detect cell viability after treatment of different concentrations of LZ-101 for 12 h, 24 h, and 48 h in A549 (b), H1299 (c) and H460 (d). e Cell viability was detected after treatment of 5, 10, and 15 μM LZ-101 for 24 h in A549, H1299, and H460 cells. f Cell viability was detected after treatment of 20 μM Q-VD-OPh or 15 μM LZ-101 for 24 h in A549, H1299, and H460 cells. Data are presented as mean ± SD. *P < 0.05, **P < 0.01 compared with DMSO group. ##P < 0.01

Back to article page